Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001212

Drug Information
NameNorethindrone    
Synonymsnorethindrone; HMS501L15; N.E.E; 17-Ethynyl-17-hydroxyestr-4-en-3-one; Norethindirone; Noriday; BSPBio_000066; Noretisterona; BRD-A39415247-001-02-1; Micronor; Triella; EINECS 200-681-6; Utovlan; Norethin 1/35 E; Norpregneninolone; Minovlar; Normapause; Norethin; 17alpha-Ethynyl-4-estren-17-ol-3-one; Nodiol; ARONIS24281; MLS001163874; Norfor; Norlutin; Synphase; 46525_RIEDEL; LMST02030097; Microneth; STOCK1N-04274; Gestest; Noraethisteronum; Synphasic 28; Norethisteron; Jenest; Ortho-Novum 1 35; HSDB 3370; Norethindrone (USP); SC 4640; Prestwick_646; SMR000499579; Micronor (TN); N.E.E.; CPD000499579; SMR000718762; C05028; Oprea1_606355; 19-Nor-17alpha-ethynyltestosterone; Ovysmen 0.5 35; Orlest; Norethisterone [Progestins]; Gencept; Nor-Q.D; Ethynylmortestosterone; Primolut-N; Ciclovulan; CID5702093; CID4536; HMS2090D21; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one; STK730956; Nelova; Norgestin; 17-Ethinyl-19-nortestosterone; Nora-BE; Noretisterona [INN-Spanish]; Conceplan; SPBio_001052; Noriday 28; D00182; Brevicon; KBio2_001491; 19-Norethindrone; 19-Nor-17alpa-ethynyltestosterone; MolPort-003-861-444; KBio2_006627; BB_NC-0600; Brevinor 28; Spectrum3_000521; AC1Q6OG5; Norethynodron; Prestwick3_000253; BPBio1_000074; KBio2_004059; Norethynodrone; Brevinor; N0449; 17-alpha-Ethynyl-19-nortestosterone; AC1O5EOU; Estrinor; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; Micronovum; Ortho 1 35; Norluten; HMS1920B10; AR-1C1071; AI3-26422; Anovule; BRD-K92073408-001-03-3; Prestwick2_000253; Nor-Q.D.; Norcept; Ortho-Novum 7 7 7; BRN 1915671; 19-Norethinyltestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; Noretisterone; Proluteasi; Errin; HMS2091J10; Conludag; Ethinyl-19-nortestosterone; Ethynylnortestosterone; Norethindrone [USAN]; Ortho 7 7 7; UNII-T18F433X4S; Genora; WLN: L E5 B666 OV MUTJ E FQ F1UU1 -A&F; Demulen; Noresthisterone; Norethisteronum; Ortho-Novum 1 50; Norpregneninotone; Norethyndron; AC1L1M2R; 17.alpha.-Ethinyl-19-nortestosterone; Norethadrone; Brevinor 21; BSPBio_002101; KBio1_000553; 17alpha-Ethynyl-19-nortestosterone; NSC9564; Norcept-E; CCRIS 484; Conludaf; MLS001304093; 19-Nortestosterone, 17-ethynyl-; N4128_SIGMA; Mini-pill; Utovlar; MolPort-002-507-131; Norethisteronum [INN-Latin]; A3564/0151191; CHEBI:7627; Loestrin; Norcolute; Norcolut; Spectrum2_001066; Primolut-N (TN); Norluton; NCGC00178820-01; 19-Nor-17-ethinyl testosterone; Norethin 1/50 M; 17alpha-Ethinyl-19-nortestosterone; IDI1_000553; MolPort-002-509-542; Spectrum4_000079; Trinovum 21; AKOS004119895; 19-Nor-17-ethinyltestosterone; component of Noriday; Activella; Noretisterone [DCIT]; SPBio_002285; Spectrum_001011; 17.alpha.-Ethynyl-19-nortestosterone; Camila; DB00717; AC1L1IDS; 19-Nor-17.alpha.-ethynyltestosterone; Menzol; AC1NWAOX; 19-Nor-ethinyl--4,5-testosterone; NSC-9564; Anovulatorio; 17-alpha-Ethynyl-4-estren-17-ol-3-one; MolPort-002-728-977; Jenest-28; Nor-QD; 46525_FLUKA; SPECTRUM1500437; 19-Nor-17-alpha-ethynyltestosterone; Primolut N; CID6432649; Prestwick1_000253; MLS001076679; Noralutin; Camila (TN); ST094767; Mini-Pe; AC-11100; CID6230; Brevinor-1 28; Norethisterone; CHEMBL1162; SAM002564223; ZINC03814419; Spectrum5_001198; 19-Nor-ethindrone; Norethisterone (JP15); Tri-Norinyl; Ovysmen 1 35; KBio3_001601; Norethindrone Norethisterone; Prestwick0_000253; KBioGR_000637; Milli; Micronett; DivK1c_000553; I06-0104; 68-22-4; KBioSS_001491; Brevinor-1 21; NCGC00179669-01; HMS1568D08; Norpregneninlone; Anhydrohydroxynorprogesterone; LS-97425; Ethinylnortestosterone; NINDS_000553    
IndicationOral contraceptiveApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassContraceptive Agents    
CAS NumberCAS 68-22-4
FormularC20H26O2    
PubChem Compound IDCID 4536.    
PubChem Substance IDSID 75017.    
ChEBI7627;    
SuperDrug ATC IDG03AC01;    
SuperDrug CAS ID000068224;    
TargetProgesterone receptorAgonist[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543